Selin Bilgic, Karol M Pencina, Michael J Pencina, Justine Cole, Line Dufresne, George Thanassoulis, Allan D Sniderman
{"title":"英国生物库和弗雷明汉研究中 VLDL-C 和载脂蛋白 B 的不一致性分析:一项前瞻性观察研究","authors":"Selin Bilgic, Karol M Pencina, Michael J Pencina, Justine Cole, Line Dufresne, George Thanassoulis, Allan D Sniderman","doi":"10.1161/ATVBAHA.124.321165","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent observational and Mendelian randomization analyses have reported significant effects of VLDL-C (very-low density lipoprotein cholesterol) on risk that is independent of ApoB (apolipoprotein B). We aim to determine the independent association of VLDL-C and ApoB with the risk of new onset cardiovascular events in the UK Biobank and Framingham Heart Study cohorts.</p><p><strong>Methods: </strong>We included 294 289 UK Biobank participants with a median age of 56 years, 42% men, and 2865 Framingham Heart Study participants (median age, 53 years; 47% men). The residual resulting from regressing VLDL-C on ApoB expresses the portion of VLDL-C not explained by ApoB, while the residual from regressing ApoB on VLDL-C expresses the portion of ApoB not explained by VLDL-C. Cox proportional hazards models for atherosclerotic cardiovascular disease incidence were created for residual VLDL-C and residual ApoB. Models were analyzed with and without high-density lipoprotein cholesterol (HDL-C). Furthermore, we investigated the independent effects of VLDL-C after accounting for ApoB and HDL-C and of HDL-C after accounting for ApoB and VLDL-C.</p><p><strong>Results: </strong>In the UK Biobank, ApoB was highly correlated with VLDL-C (r=0.70; <i>P</i><0.001) but weakly negatively correlated with HDL-C (r=-0.11; <i>P</i><0.001). The ApoB residual and the VLDL-C residual were significantly associated with new-onset atherosclerotic cardiovascular disease (hazard ratio [HR], 1.08 and 1.05, respectively; <i>P</i><0.001). After adjusting for HDL-C, the ApoB residual remained similar in magnitude (HR, 1.10; <i>P</i><0.001), whereas the effect size of the VLDL-C residual was reduced (HR, 1.02; <i>P</i>=0.029). The independent effect of HDL-C (after accounting for ApoB and VLDL-C) remained robust (HR, 0.86; <i>P</i><0.0001), while the independent effect of VLDL-C (after accounting for ApoB and HDL-C) was modest (HR, 1.02; <i>P</i>=0.029). All results were consistent in the Framingham cohort.</p><p><strong>Conclusions: </strong>When adjusted for HDL-C, the association of VLDL-C with cardiovascular risk was no longer clinically meaningful. Our residual discordance analysis suggests that adjustment for HDL-C cannot be ignored.</p>","PeriodicalId":8401,"journal":{"name":"Arteriosclerosis, Thrombosis, and Vascular Biology","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discordance Analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: A Prospective Observational Study.\",\"authors\":\"Selin Bilgic, Karol M Pencina, Michael J Pencina, Justine Cole, Line Dufresne, George Thanassoulis, Allan D Sniderman\",\"doi\":\"10.1161/ATVBAHA.124.321165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recent observational and Mendelian randomization analyses have reported significant effects of VLDL-C (very-low density lipoprotein cholesterol) on risk that is independent of ApoB (apolipoprotein B). We aim to determine the independent association of VLDL-C and ApoB with the risk of new onset cardiovascular events in the UK Biobank and Framingham Heart Study cohorts.</p><p><strong>Methods: </strong>We included 294 289 UK Biobank participants with a median age of 56 years, 42% men, and 2865 Framingham Heart Study participants (median age, 53 years; 47% men). The residual resulting from regressing VLDL-C on ApoB expresses the portion of VLDL-C not explained by ApoB, while the residual from regressing ApoB on VLDL-C expresses the portion of ApoB not explained by VLDL-C. Cox proportional hazards models for atherosclerotic cardiovascular disease incidence were created for residual VLDL-C and residual ApoB. Models were analyzed with and without high-density lipoprotein cholesterol (HDL-C). Furthermore, we investigated the independent effects of VLDL-C after accounting for ApoB and HDL-C and of HDL-C after accounting for ApoB and VLDL-C.</p><p><strong>Results: </strong>In the UK Biobank, ApoB was highly correlated with VLDL-C (r=0.70; <i>P</i><0.001) but weakly negatively correlated with HDL-C (r=-0.11; <i>P</i><0.001). The ApoB residual and the VLDL-C residual were significantly associated with new-onset atherosclerotic cardiovascular disease (hazard ratio [HR], 1.08 and 1.05, respectively; <i>P</i><0.001). After adjusting for HDL-C, the ApoB residual remained similar in magnitude (HR, 1.10; <i>P</i><0.001), whereas the effect size of the VLDL-C residual was reduced (HR, 1.02; <i>P</i>=0.029). The independent effect of HDL-C (after accounting for ApoB and VLDL-C) remained robust (HR, 0.86; <i>P</i><0.0001), while the independent effect of VLDL-C (after accounting for ApoB and HDL-C) was modest (HR, 1.02; <i>P</i>=0.029). All results were consistent in the Framingham cohort.</p><p><strong>Conclusions: </strong>When adjusted for HDL-C, the association of VLDL-C with cardiovascular risk was no longer clinically meaningful. Our residual discordance analysis suggests that adjustment for HDL-C cannot be ignored.</p>\",\"PeriodicalId\":8401,\"journal\":{\"name\":\"Arteriosclerosis, Thrombosis, and Vascular Biology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arteriosclerosis, Thrombosis, and Vascular Biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1161/ATVBAHA.124.321165\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arteriosclerosis, Thrombosis, and Vascular Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/ATVBAHA.124.321165","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/15 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:最近的观察性分析和孟德尔随机分析报告了极低密度脂蛋白胆固醇(VLDL-C)对风险的显著影响,而这种影响与载脂蛋白B无关:在英国生物库和弗雷明汉心脏研究队列中确定 VLDL-C 和载脂蛋白与新发心血管事件风险的独立关联:我们纳入了 294 289 名英国生物库参与者(中位年龄 56 岁,42% 为男性)和 2865 名弗雷明汉心脏研究参与者(中位年龄 52 岁,47% 为男性)。将 VLDL-C 对载脂蛋白 B 进行回归得到的残差表示 VLDL-C 中载脂蛋白 B 无法解释的部分,而将载脂蛋白 B 对 VLDL-C 进行回归得到的残差表示载脂蛋白 B 中 VLDL-C 无法解释的部分。针对残余 VLDL-C 和残余载脂蛋白建立了动脉粥样硬化性心血管疾病发病率的 Cox 比例危险模型。分析了有高密度脂蛋白胆固醇(HDL-C)和无高密度脂蛋白胆固醇(HDL-C)的模型。此外,我们还研究了VLDL-C对载脂蛋白B和高密度脂蛋白胆固醇的独立影响,以及HDL-C对载脂蛋白B和VLDL-C的独立影响:在英国生物库中,载脂蛋白B与 VLDL-C 高度相关(r=0.70;PPPPP=0.029)。HDL-C的独立效应(考虑载脂蛋白B和VLDL-C后)仍然很强(HR,0.86;PPP=0.029)。所有结果在弗雷明汉队列中都是一致的:经高密度脂蛋白胆固醇调整后,VLDL-C 与心血管风险的关系不再具有临床意义。我们的残差分析表明,不能忽视对高密度脂蛋白胆固醇的调整。
Discordance Analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: A Prospective Observational Study.
Background: Recent observational and Mendelian randomization analyses have reported significant effects of VLDL-C (very-low density lipoprotein cholesterol) on risk that is independent of ApoB (apolipoprotein B). We aim to determine the independent association of VLDL-C and ApoB with the risk of new onset cardiovascular events in the UK Biobank and Framingham Heart Study cohorts.
Methods: We included 294 289 UK Biobank participants with a median age of 56 years, 42% men, and 2865 Framingham Heart Study participants (median age, 53 years; 47% men). The residual resulting from regressing VLDL-C on ApoB expresses the portion of VLDL-C not explained by ApoB, while the residual from regressing ApoB on VLDL-C expresses the portion of ApoB not explained by VLDL-C. Cox proportional hazards models for atherosclerotic cardiovascular disease incidence were created for residual VLDL-C and residual ApoB. Models were analyzed with and without high-density lipoprotein cholesterol (HDL-C). Furthermore, we investigated the independent effects of VLDL-C after accounting for ApoB and HDL-C and of HDL-C after accounting for ApoB and VLDL-C.
Results: In the UK Biobank, ApoB was highly correlated with VLDL-C (r=0.70; P<0.001) but weakly negatively correlated with HDL-C (r=-0.11; P<0.001). The ApoB residual and the VLDL-C residual were significantly associated with new-onset atherosclerotic cardiovascular disease (hazard ratio [HR], 1.08 and 1.05, respectively; P<0.001). After adjusting for HDL-C, the ApoB residual remained similar in magnitude (HR, 1.10; P<0.001), whereas the effect size of the VLDL-C residual was reduced (HR, 1.02; P=0.029). The independent effect of HDL-C (after accounting for ApoB and VLDL-C) remained robust (HR, 0.86; P<0.0001), while the independent effect of VLDL-C (after accounting for ApoB and HDL-C) was modest (HR, 1.02; P=0.029). All results were consistent in the Framingham cohort.
Conclusions: When adjusted for HDL-C, the association of VLDL-C with cardiovascular risk was no longer clinically meaningful. Our residual discordance analysis suggests that adjustment for HDL-C cannot be ignored.
期刊介绍:
The journal "Arteriosclerosis, Thrombosis, and Vascular Biology" (ATVB) is a scientific publication that focuses on the fields of vascular biology, atherosclerosis, and thrombosis. It is a peer-reviewed journal that publishes original research articles, reviews, and other scholarly content related to these areas. The journal is published by the American Heart Association (AHA) and the American Stroke Association (ASA).
The journal was published bi-monthly until January 1992, after which it transitioned to a monthly publication schedule. The journal is aimed at a professional audience, including academic cardiologists, vascular biologists, physiologists, pharmacologists and hematologists.